Gilead Sciences, Inc.GILD
NasdaqGS•Healthcare•Drug Manufacturers - General
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $29.74B, growing 3.5% year-over-year. TTM net income stood at $9.22B (54.5% growth). Quarterly EBITDA was $2.59B and operating income was $2.59B. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze GILD growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters